Company Filing History:
Years Active: 2013-2014
Title: Hotaka Hashimoto: Innovator in Cancer Chemotherapy
Introduction
Hotaka Hashimoto is a notable inventor based in Ibaraki, Japan. He has made significant contributions to the field of cancer treatment through his innovative formulations of anthracycline compounds. With a total of 2 patents, his work focuses on improving the stability and efficacy of chemotherapeutic agents.
Latest Patents
Hashimoto's latest patents include a "Stabilized and lyophilized formulation of anthracycline compounds." This invention provides a lyophilized amrubicin formulation and a process that controls the concentration of the aqueous solution before lyophilization to about 7.5 mg(potency)/mL or more. This formulation decreases the production of desaccharified compounds and is stable for long-term storage, making it useful as a cancer chemotherapeutic agent. Another significant patent is the "Freeze-dried preparation of stabilized anthracycline compound." This invention offers a lyophilized preparation of amrubicin that contains L-cysteine or a salt thereof, with a water content of 0 to about 4% by weight. This preparation is stable even during long-term storage and serves as a chemotherapeutic agent for cancers.
Career Highlights
Throughout his career, Hashimoto has worked with prominent companies, including Dainippon Sumitomo Pharma Co., Ltd. and Dainippon Sumitomo Pharma. His experience in these organizations has contributed to his expertise in pharmaceutical innovations.
Collaborations
Hashimoto has collaborated with notable coworkers such as Hajimu Hirofuji and Kazunari Tanaka. Their combined efforts have further advanced the development of effective cancer treatments.
Conclusion
Hotaka Hashimoto's contributions to the field of cancer chemotherapy through his innovative patents highlight his dedication to improving patient outcomes. His work continues to influence the development of stable and effective treatments for cancer.